FDA
-
-
-
-
-
-
-
Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio
-
-
-
-
-
-
-
IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization
-
-
-
-
-
-
-
Second Study Affirms Superiority of iMDx GraftAssure Assay’s Proprietary dd-cfDNA Combination Model Score
-
-
-
-
-
-
-
iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch
-
-
-
-
-
-
-
IMDX CFO Andrea James Featured in Empowered Patient Podcast on Democratizing Molecular Diagnostics
-
-
-
-
-
-
-
Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville
329,910 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

